Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study

Abstract Introduction Ixekizumab (IXE) is an IgG4-type monoclonal antibody targeting IL-17A indicated alone or in combination with methotrexate, for the treatment of active psoriatic arthritis (PsA) in adult patients with insufficient response or with intolerance to one or more disease-modifying ant...

Descripció completa

Dades bibliogràfiques

Autors principals:	Beatriz Joven, Raquel Hernández Sánchez, Eva Pérez-Pampín, Ángel Aragón Díez, Raquel Almodóvar, Ángels Martínez-Ferrer, Joaquín Belzunegui, Esteban Rubio, Silvia Díaz-Cerezo, Sebastián Moyano, Manuel Gómez-Barrera, María Yébenes, Mercedes Núñez
Format:	Artigo
Idioma:	Inglês
Publicat:	Adis, Springer Healthcare 2023-07-01
Col·lecció:	Rheumatology and Therapy
Matèries:	Ixekizumab Persistence Effectiveness Psoriatic arthritis Real-world study
Accés en línia:	https://doi.org/10.1007/s40744-023-00584-8
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!